Mangoceuticals (MGRX) Income from Continuing Operations (2023 - 2026)

Mangoceuticals has disclosed Income from Continuing Operations across 4 years of filings, most recently posting -$1.3 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 75.76% year-over-year to -$1.3 million; the TTM figure through Jun 2026 stood at -$15.1 million (down 6.34% YoY), while the FY2025 annual figure was -$16.3 million, down 137.08% from the prior year.
• Income from Continuing Operations came in at -$1.3 million for Q2 2026 at Mangoceuticals, up from -$3.4 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of -$1.3 million in Q2 2026 to a low of -$7.6 million in Q3 2025.
• Average Income from Continuing Operations over 4 years is -$3.1 million, with a median of -$2.5 million recorded in 2023.
• Year-over-year, Income from Continuing Operations plunged 281.0% in 2025 and soared 75.76% in 2026.
• Over 4 years, Income from Continuing Operations stood at -$2.6 million in 2023, then climbed by 24.12% to -$1.9 million in 2024, then sank by 42.12% to -$2.8 million in 2025, then jumped by 52.59% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$1.3 million in Q2 2026, -$3.4 million in Q1 2026, and -$2.8 million in Q4 2025.